Precise Diagnostics, INC.

Precise Diagnostics, INC. was paid $2.04M by Medicaid between Jan 2018 and Nov 2024, across 51 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 42% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#45 of 116

Median peer was paid$618K

This provider vs. median3.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,973	$30K
2019	6,796	$94K
2020	7,718	$155K
2021	28,115	$795K
2022	23,225	$741K
2023	2,265	$127K
2024incomplete	1,383	$100K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	42%	12,574	11,445	$855K
88305	Level IV - Surgical pathology, gross and microscopic examination	18%	7,170	6,934	$366K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	8.3%	8,953	8,311	$170K
88342		6.3%	2,119	2,106	$129K
88312		6.3%	3,705	3,622	$128K
88112		2.8%	2,425	2,358	$58K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	2.6%	2,681	2,376	$54K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.8%	1,773	1,766	$37K
88142		1.8%	1,782	1,780	$37K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.3%	1,334	1,333	$26K
87660		1.2%	1,839	1,838	$24K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.1%	1,319	1,317	$22K

39 more codes

88141		<1%	1,797	$14K
87510		<1%	1,316	$13K
87480		<1%	1,300	$13K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,908	$12K
88313		<1%	1,470	$10K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	310	$10K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	9,135	$8K
88120		<1%	44	$7K
87086	Culture, bacterial; quantitative colony count, urine	<1%	991	$5K
83036	Hemoglobin; glycosylated (A1C)	<1%	472	$4K
80053	Comprehensive metabolic panel	<1%	496	$4K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	75	$4K
84443	Thyroid stimulating hormone (TSH)	<1%	336	$4K
80061	Lipid panel	<1%	459	$2K
82607		<1%	216	$2K
87077		<1%	370	$2K
87088		<1%	371	$2K
80050	General health panel	<1%	60	$2K
81001		<1%	570	$2K
87625		<1%	70	$2K
84439		<1%	248	$2K
88369		<1%	32	$2K
87186		<1%	372	$2K
99213	Doctor's office visit, returning patient (routine)	<1%	14	$1K
82746		<1%	95	$1K
88368		<1%	34	$987.05
84481		<1%	130	$927.00
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	267	$667.99
84436		<1%	95	$381.90
82043		<1%	93	$352.10
82728		<1%	32	$290.50
84479		<1%	85	$207.90
86140		<1%	61	$197.95
83540		<1%	27	$161.78
84702		<1%	14	$160.81
83550		<1%	15	$112.67
99001		<1%	388	$4.26
99000		0%	19	$0.00
99072		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHAMEED, ARIF (PRESIDENT)